Louisiana has picked its 'Netflix' hepatitis C partner: Gilead's new generics unit

louisiana
Officials in Louisiana selected a Gilead subsidiary to be the state's partner to supply hepatitis C drugs. (Stuart Seeger on Flickr/CC BY 2.0)

Health and corrections officials in Louisiana are one step closer to treating thousands of hepatitis C patients who previously haven't had access to the latest drugs. The state chose Gilead Sciences’ new generics business, Asegua Therapeutics, to team up on its “Netflix” subscription model for unlimited access to an authorized Epclusa copycat. 

Louisiana made the selection official on Tuesday and said it hopes to have a contract signed by June 1. The 5-year partnership would then start July 1. Louisiana wants to treat more than 10,000 hepatitis C patients on Medicaid and in the state's prisons by the end of 2020. 

State officials say current payment systems don’t adequately fund the drugs needed to treat those patients. Last year, less than 3% of hepatitis C patients on Medicaid gained access to treatment, the state said.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

By paying a fixed cost for the contract, the state will be able to accurately budget for its spending and prevent future spread of hepatitis C at the same time. For drug companies, the contract offers access to patient groups that aren’t served by traditional drug funding systems. 

Gilead’s chief patient officer Gregg Alton said in a statement his company looks “forward to working on an agreement for this groundbreaking subscription model to increase access to a cure for people living with hepatitis C in Louisiana.” 

RELATED: Louisiana's 'Netflix' deal for hepatitis C drugs wins bids from AbbVie, Gilead and Merck 

Gilead won the deal over Merck and AbbVie, which each submitted bids for the state’s subscription model. Louisiana has been weighing the strategy since at least last year and rolled out a request for comments in August. Before that, the state explored treating hepatitis C patients with assistance from the federal government but opted not to go that route.

Now, Louisiana isn’t alone in pursuing the subscription strategy: Washington state is also proposing a “winner-take-all" contract for hepatitis C drugs. That state has said it plans to announce its partner in April. 

RELATED: Washington takes 'Netflix' hep C drug pricing further with winner-take-all bidding 

For Gilead, the contract represents a new revenue stream in a field where it once made a fortune—but not anymore. Gilead's hepatitis C sales have plummeted, thanks to competition that ate into its market share and seriously curtailed its pricing power. The situation has grown so bad for Gilead that it took the unusual step of launching authorized generics to its own drugs in an effort to boost access and reach new patients. 

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.